logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Hypogonadism

    FiltersReset Filters
    16 results

    • azmiro

      (TESTOSTERONE CYPIONATE)
      Azurity Pharmaceuticals, Inc.
      Usage: AZMIRO is indicated for testosterone replacement therapy in males with conditions causing testosterone deficiency, including primary hypogonadism (e.g., testicular failure, Klinefelter’s syndrome) and hypogonadotropic hypogonadism (e.g., pituitary-hypothalamic injury). The safety and efficacy for age-related hypogonadism and pediatric patients under 12 are not established.

    • bromocriptine mesylate

      (Bromocriptine mesylate)
      Zydus Pharmaceuticals USA Inc.
      Usage: Bromocriptine mesylate capsules are indicated for treating hyperprolactinemia-related disorders (e.g., amenorrhea, infertility, hypogonadism), acromegaly, and symptoms of Parkinson's disease. It may be used with levodopa to enhance efficacy and reduce side effects, especially in patients experiencing tolerance or "end of dose failure."

    • bromocriptine mesylate

      (Bromocriptine mesylate)
      Sandoz Inc
      Usage: Bromocriptine mesylate tablets are indicated for treating hyperprolactinemia-related dysfunctions (e.g., amenorrhea, infertility), acromegaly, and symptoms of Parkinson's disease. They help reduce tumor size in prolactin-secreting adenomas and enhance effects of levodopa in Parkinson's, while potentially reducing levodopa dosage and adverse reactions.

    • climara

      (Estradiol)
      Bayer HealthCare Pharmaceuticals Inc.
      Usage: This drug is indicated for the treatment of moderate to severe vasomotor symptoms and vulvar/vaginal atrophy due to menopause, hypoestrogenism from hypogonadism or primary ovarian failure, and for the prevention of postmenopausal osteoporosis, with specific limitations on its use for atrophy and osteoporosis.

    • depo-testosterone

      (testosterone cypionate)
      Pharmacia and Upjohn Company LLC
      Usage: DEPO-Testosterone Injection is indicated for replacement therapy in men with testosterone deficiency due to primary hypogonadism (e.g., testicular failure) or hypogonadotropic hypogonadism (e.g., gonadotropin deficiency). Its safety and efficacy for "age-related hypogonadism" have not been established.

    • estradiol transdermal system

      (Estradiol)
      Sandoz Inc
      Usage: The Estradiol Transdermal System is indicated for treating moderate to severe vasomotor symptoms and vulvar/vaginal atrophy due to menopause, hypoestrogenism from various causes, and prevention of postmenopausal osteoporosis, with specific limitations for certain conditions.

    • kyzatrex

      (TESTOSTERONE UNDECANOATE)
      Marius Pharmaceuticals
      Usage: KYZATREX™ is indicated for testosterone replacement therapy in adult males with testosterone deficiency due to primary hypogonadism (e.g., testicular failure) or hypogonadotropic hypogonadism (e.g., pituitary-hypothalamic injury). Safety and efficacy in males under 18 have not been established.

    • methyltestosterone

      (METHYLTESTOSTERONE)
      Amneal Pharmaceuticals of New York LLC
      Usage: Androgens are indicated for testosterone replacement therapy in males with primary and hypogonadotropic hypogonadism, and for stimulating puberty in selected cases. In females, they are used in treating advanced inoperable metastatic breast cancer post-menopause. Treatment decisions should involve expert judgment, especially in oncology.

    • testosterone

      (Testosterone)
      Dr. Reddy's Laboratories Inc.
      Usage: Testosterone gel 1.62% is indicated for replacement therapy in adult males with primary or hypogonadotropic hypogonadism due to conditions like testicular failure or pituitary-hypothalamic injury. Its safety and efficacy for age-related hypogonadism and in males under 18 have not been established.

    • testosterone

      (Testosterone)
      Upsher-Smith Laboratories, LLC
      Usage: Testosterone gel is indicated for replacement therapy in adult males with testosterone deficiency due to primary or hypogonadotropic hypogonadism. Conditions include testicular failure, pituitary-hypothalamic injury, and other related conditions. Safety and efficacy in age-related hypogonadism and in males under 18 have not been established.